Profit after tax grew by 120.9 per cent to Rs 651 crore, up from Rs 295 crore
Cipla has announced its unaudited consolidated financial results for the quarter ended June 30, 2015. Income from operations grew by 41.6 per cent to Rs 3,853 crore, up from Rs 2,720 crore. EBITDA grew by 91.8 per cent to Rs 1039 crore, up from Rs. 542 crore. Profit after tax grew by 120.9 per cent to Rs 651 crore, up from Rs 295 crore.
Material cost is at 32.5 per cent of income from operations in Q1 FY15-16 as compared to 37.7 per cent in Q1 FY14-15. EBIDTA as percentage of income from operations increased to 27 per cent in Q1 FY1516 from 19.9 per cent in Q1 FY14-15. Profit after tax grew by 120.9 per cent to Rs 651 crore, up from Rs 295 crore in Q1 FY14-15. The results for the current period includes one-off revenue from the US market.
Domestic sales grew by 8.4 per cent to Rs 1,397 crore during Q1 FY15-16, up from Rs 1,289 crore during Q1 FY14-15. The growth in domestic sales was largely on account of growth in respiratory, anti-infectives, cardiac and gastro intestinal therapies.
Exports of formulations increased by 78.5 per cent to Rs 2,174 crore during Q1 FY15-16, from Rs 1,218 crore during Q1 FY14-15. Exports of APIs increased by 47 per cent to Rs 206 crore during Q1 FY15-16, from Rs 140 crore during Q1 FY14-15.